title: Long-term outcome of patients with acromegaly and congestive heart failure.
abstract: Cardiovascular complications are a major cause of morbidity and mortality in patients with acromegaly. Normalization of GH secretion is associated with an improvement in structural and functional cardiac abnormalities. However, the long-term cardiac effects of treatment for acromegaly have not been studied in patients who have already developed chronic congestive heart failure (CHF). We reviewed the charts of 330 consecutive patients with acromegaly treated in two French and Belgian centers since 1985. Ten patients with both acromegaly and CHF (eight men, two women, mean age 49.7 yr) were studied retrospectively. One of them was excluded because CHF was due to severe aortic stenosis.CHF (New York Heart Association stages III-IV and echocardiography showing dilated hypokinetic cardiomyopathy with left ventricular systolic dysfunction and a left ventricular ejection fraction less than 45%) was diagnosed before, concomitantly, or after acromegaly in, respectively, two, five, and two patients. Three patients were referred with terminal heart failure requiring transplantation.One patient had transient CHF associated with a hypertensive crisis. The other eight patients had symptomatic chronic CHF. Control of GH hypersecretion failed, totally or partially, in three patients: one had a long-term survival, and the two others died at 1 and 5 yr. Good GH control was achieved in five patients: four of these are still alive 2-16 yr after diagnosis of CHF, their clinical status is stable or improved, and their quality of life is good. Overall, the 1- and 5-yr mortality (or transplantation) rates for patients with chronic symptomatic CHF were 25% (2 of 8 patients) and 37.5% (3 of 8 patients), respectively. In conclusion, less than 3% of acromegalic patients developed CHF in this study. Although effective treatment of acromegaly improved short-term cardiovascular status, its impact on long-term survival is questionable.
authors.affiliation: Department of Endocrinology, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, University Paris XI, 78 rue du Général Leclerc, F-94275 Le Kremlin-Bicêtre, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Bihan
authors.forename: Consuelo
authors.initials: C
authors.lastname: Espinosa
authors.forename: Hernan
authors.initials: H
authors.lastname: Valdes-Socin
authors.forename: Sylvie
authors.initials: S
authors.lastname: Salenave
authors.forename: Jacques
authors.initials: J
authors.lastname: Young
authors.forename: Suzanne
authors.initials: S
authors.lastname: Levasseur
authors.forename: Patrick
authors.initials: P
authors.lastname: Assayag
authors.forename: Albert
authors.initials: A
authors.lastname: Beckers
authors.forename: Philippe
authors.initials: P
authors.lastname: Chanson
mesh_terms: D000172:Acromegaly / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D000328:Adult; D005260:Female; D006333:Heart Failure / Q000209:etiology*; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D011379:Prognosis; D018487:Ventricular Dysfunction, Left
chemical_list: D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I